Effects of tacrolimus on IFN-γ signaling in keratinocytes: Possible mechanisms by which tacrolimus affects IFN-γ-dependent skin inflammation

European Journal of Dermatology

Volumn 21, Issue 1, 2011, Pages 22-31

  Tu, Hong Qin ^a,b   Li, Xin Yu ^a   Tang, Mei Yu ^a   Gao, Ji Wei ^a   Xu, Lan Fang ^a   Chen, Zhi Qiang ^a   Gu, Heng ^a  

^a INSTITUTE OF DERMATOLOGY   (China)

^b YIXING PEOPLE S HOSPITAL   (China)

Author keywords

Interferon gamma; Janus kinase; Keratinocytes; Signal transducer and activator of transcription; Suppressors of cytokine signaling; Tacrolimus

Indexed keywords

GAMMA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR ALPHA; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; JANUS KINASE 2; RECOMBINANT GAMMA INTERFERON; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TACROLIMUS; UNCLASSIFIED DRUG; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; JAK2 PROTEIN, HUMAN; SOCS1 PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; KERATINOCYTE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; SIGNAL TRANSDUCTION; SKIN INFLAMMATION; UPREGULATION; CELL SURVIVAL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; PHYSIOLOGY;

CELL SURVIVAL; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HLA-DR ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-GAMMA; INTERLEUKIN-8; JANUS KINASE 2; KERATINOCYTES; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TACROLIMUS; UP-REGULATION;

EID: 79957471508     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.1154     Document Type: Article

References (38)

1. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life. Arch Dermatol 2001; 137: 280-4.
2. Hutchings CV, Shum KW, Gawkrodger DJ. Occupational contact dermatitis has an appreciable impact on quality of life. Contact Dermatitis 2001; 45: 17-20.
3. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20: 40-6.
4. Cavani A, Albanesi C, Traidl C, Sebastiani S, Girolomoni G. Effector and regulatory T cells in allergic contact dermatitis. Trends Immunol 2001; 22: 118-20.
5. Li J, Ireland GW, Farthing PM, Thornhill MH. Epidermal and oral keratinocytes are induced to produce RANTES and CXCL8 by cytokine stimulation. J Invest Dermatol 1996; 106: 661-6.
6. James E, Darnell J. STATs and gene regulation. Science 1997; 277: 1630-5.
7. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signaling. Nature 1997; 387: 917-21.
8. Cooney RN. Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/STAT pathway. Shock 2002; 17: 83-90.
9. Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997; 387: 924-9.
10. Friedrich M, Holzmann R, Sterry W, et al. Ultraviolet B radiation-mediated inhibition of interferon-γ-induced keratinocyte activation is independent of interleukin-10 and other soluble mediators but associated with enhanced intracellular suppressors of cytokine-signaling expression. J Invest Dermatol 2003; 121: 845-52.
11. Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol 1987; 139: 1797-803.
12. Abu-Elmagd K, Van Thiel D, Jegasothy BV, et al. FK 506: a new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc 1991; 23: 3322-4.
13. Thomson AW, Nalesnik MA, Rilo HR, Woo J, Carroll PB, Van Thiel DH. ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK-506 therapy. Autoimmunity 1993; 15: 215-23.
14. Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Abu-Elmagd K, Starzl TE. Tacrolimus (FK 506)-a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992; 128: 781-5.
15. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998; 102: 637-44.
16. Reitamo S. Tacrolimus: a new topical immunomodulatory therapy for atopic dermatitis. J Allergy Clin Immunol 2001; 107: 445-8.
17. Wollenberg A, Reitamo S, Girolomoni G, et al. European Tacrolimus Ointment Study Group. Allergy 2008; 63: 742-50.
18. Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51: 723-30.
19. Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 2005; 141: 43-6.
20. Schliemann S, Kelterer D, Bauer A, et al. Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. Contact Dermatitis 2008; 58: 299-306.
21. Freeman AK, Serle J, VanVeldhuisen P, et al. Tacrolimus ointment in the treatment of eyelid dermatitis. Cutis 2004; 73: 267-71.
22. Reynolds NJ, Al-Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol 2002; 27: 555-61.
23. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
24. Winiski AP, Foster CA. ICAM-1 expression in a spontaneously transformed human keratinocyte cell line: characterization by a simple cell-ELISA assay. J Invest Dermatol 1992; 99: 48-52.
25. Girolomoni G, Sebastiani S, Albanesi C, Cavani A. T-cell subpopulations in the development of atopic and contact allergy. Cur Opin Immunol 2001; 13: 733-7.
26. Albanesi C, Scarponi C, Giustizieri ML, Girolomoni G. Keratinocytes in inflammatory skin diseases. Current Drug Targets-Inflammation & Allergy 2005; 4: 329-34.
27. Albanesi C, Scarponi C, Sebastiani S, et al. A cytokine-tochemokine axis between T lymphocytes and keratinocytes can favor Th1 cell accumulation in chronic inflammatory skin diseases. J Leukocyte Biol 2001; 70: 617-23.
28. Federici M, Giustizieri ML, Scarponi C, Girolomoni G, Albanesi C. Impaired IFN-γ-dependent inflammatory responses in human keratinocytes overexpressing the suppressor of cytokine signaling. J Immunol 2002; 168: 434-42.
29. Larkin J, Johnson HM, Subramaniam PS. Differential nuclear localization of the IFNGR-1 and IFNGR-2 subunits of IFN-γ receptor complex following activation by IFN-γ. J Interferon Cytokine Res 2000; 20: 565-76.
30. Subramaniam PS, Larkin J, Mujtaba MG, Walter MR, Johnson HM. The COOH-terminal nuclear localization sequence of interferon-γ regulates STAT1 nuclear translocation at an intracellular site. J Cell Sci 2000; 113: 2771-81.
31. Ahmed CM, Burkhart MA, Mujtaba MG, Subramaniam PS, Johnson HM. The role of IFN-γ nuclear localization sequence in intracellular function. J Cell Sci 2003; 116: 3089-98.
32. Walter MJ, Look DC, Tidwell RM, Roswit WT, Holtzman MJ. Targeted inhibition of interferon-γ-dependent intercellular adhesion molecule-1 (ICAM-1) expression using dominant-negative Stat1. J Biol Chem 1997; 272: 28582-9.
33. Laver T, Nozell SE, Benveniste EN. IFN-beta-mediated inhibition of CXCL8 expression requires the ISGF3 components Stat1, Stat2, and IRF-9. J Interferon Cytokine Res 2008; 28: 13-23.
34. Singer KH, Tuck DT, Sampson HA, Hall RP. Epidermal keratinocytes express the adhesion molecule intercellular adhesion molecule-1 in inflammatory dermatoses. J Invest Dermatol 1989; 92: 746-50.
35. Strange P, Skov L, Baadsgaard O. Interferon gamma-treated keratinocytes activate T cells in the presence of superantigens: Involvement of major histocompatibility complex class II molecules. J Invest Dermatol 1994; 102: 150-4.
36. Nicola NA, Greenhalgh CJ. The suppressors of cytokine signaling (SOCS) proteins: important feedback inhibitors of cytokine action. Exp Hematol 2000; 28: 1105-12.
37. Krebs DL, Hilton DJ. SOCS: physiological suppressors of cytokine signaling. J Cell Sci 2000; 113: 2813-9.
38. Yamasaki K, Hanakawa Y, Tokumaru S, Shirakata Y, Sayama K, Hanada T. Suppressor of cytokine signaling 1/JAB and suppressor of cytokine signaling 3/cytokine-inducible SH2 containing protein 3 negatively regulate the signal transducers and activators of transcription signaling pathway in normal human epidermal keratinocytes. J Invest Dermatol 2003; 120: 571-80.